Imigran Recovery | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Imigran Recovery
Health Canada Patents

Veranova: A CDMO that manages complexity with confidence.

Contact Supplier

Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Contact Supplier

pharmacompass-1-m-2025-08-25

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

pharmacompass-2-m-2025-08-25

Imigran Recovery

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

57 API Suppliers, 26 USDMF, 14 CEP/COS, 4 JDMF, 17 EU WC, 6 KDMF, 18 NDC API, 24 Listed Suppliers, $ API Reference Price

57 API Suppliers
26 USDMF
14 CEP/COS
4 JDMF
17 EU WC
6 KDMF
18 NDC API
24 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

33 Drugs in Development

33 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

397 FDF Dossiers, 103 FDA Orange Book, 212 Europe, 33 Canada, 15 Australia, 19 South Africa, 15 Listed Dossiers

397 FDF Dossiers
103 FDA Orange Book
212 Europe
33 Canada
15 Australia
19 South Africa
15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 25MG BASE, TABLET;ORAL - EQ 50MG BASE, SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR, POWDER;NASAL - EQ 11MG BASE, SPRAY;NASAL - 20MG/SPRAY, SPRAY;NASAL - 5MG/SPRAY, TABLET;ORAL - 500MG;EQ 85MG BASE, TABLET;ORAL - 60MG;EQ 10MG BASE, INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)
INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 100MG BASE
TABLET;ORAL - EQ 25MG BASE
TABLET;ORAL - EQ 50MG BASE
SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR
POWDER;NASAL - EQ 11MG BASE
SPRAY;NASAL - 20MG/SPRAY
SPRAY;NASAL - 5MG/SPRAY
TABLET;ORAL - 500MG;EQ 85MG BASE
TABLET;ORAL - 60MG;EQ 10MG BASE
INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)
INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

2 Kirsch Pharma, 1 Actylis, 1 Finar

2 Kirsch Pharma
1 Actylis
1 Finar

EXCIPIENTS BY APPLICATIONS

3 Parenteral, 1 Topical

3 Parenteral
1 Topical

DIGITAL CONTENT

35 News #PharmaBuzz

35 News #PharmaBuzz

GLOBAL SALES INFORMATION

31 US Medicaid Prescriptions, 178 Regulatory FDF Prices, 8 Annual Reports

31 US Medicaid Prescriptions
178 Regulatory FDF Prices
8 Annual Reports

MARKET PLACE

13 APIs, 1 FDF Dossiers

13 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

49 US Patents, 3 Health Canada Patents

49 US Patents
3 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 6 Others

3 EDQM
6 Others

$ API Ref.Price (USD/KG) : 1,162 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

3 All

01 2GlaxoSmithKline Inc.

02 1Smart & Biggar

filter Patent Reset all filters

3 All

01 22469019

02 12509023

filter Product Reset all filters

3 All

01 1SUMATRIPTAN SUCCINATE | NAPROXEN SODIUM

02 2Sumatriptan Succinate

filter Dosage Reset all filters

3 All

01 1TABLET

02 2Tablet

filter Exp Date Reset all filters

3 All

01 22022-12-04

02 12023-12-22

Product Main Page

01

GlaxoSmithKline Inc.

Sumatriptan

Peptide Process CMC

Not Confirmed

GlaxoSmithKline Inc.

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2022-12-04

Date Granted : 2005-09-13

Sumatriptan

Brand Name : IMITREX DF

Patent Number : 2469019

Filing Date : 2002-12-04

Strength per Unit : 50mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2022-12-04

Date Granted : 2005-09-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

GlaxoSmithKline Inc.

Sumatriptan

Peptide Process CMC

Not Confirmed

GlaxoSmithKline Inc.

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2022-12-04

Date Granted : 2005-09-13

Sumatriptan

Brand Name : IMITREX DF

Patent Number : 2469019

Filing Date : 2002-12-04

Strength per Unit : 100mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2022-12-04

Date Granted : 2005-09-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Smart & Biggar

Sumatriptan, Naproxen Sodium

Peptide Process CMC

Not Confirmed

Smart & Biggar

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2023-12-22

Date Granted : 2011-05-24

Sumatriptan, Naproxen Sodium

Brand Name : SUVEXX

Patent Number : 2509023

Filing Date : 2003-12-22

Strength per Unit : 85 mg / 500 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2023-12-22

Date Granted : 2011-05-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!